Latest MicuRx Pharmaceuticals Inc. Stories
-- Phase 1 Studies Confirm Superior Safety Profile of MRX-I Over Zyvox® -- HAYWARD, Calif. and SHANGHAI, Feb.
HAYWARD, Calif. and SHANGHAI, April 6 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc.
UNION CITY, Calif. and SHANGHAI, China, Aug. 18 /PRNewswire-FirstCall/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the nomination of MRX- I as its first preclinical development candidate.